CINECA IRIS Institutional Research Information System

VALERIO, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.332
EU - Europa 1.824
AS - Asia 367
AF - Africa 129
SA - Sud America 18
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.676
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.290
IT - Italia 662
DE - Germania 412
SE - Svezia 335
GB - Regno Unito 142
CN - Cina 133
BG - Bulgaria 129
CI - Costa d'Avorio 75
AT - Austria 57
SG - Singapore 50
VN - Vietnam 50
SN - Senegal 40
IN - India 38
CA - Canada 31
TR - Turchia 30
RU - Federazione Russa 20
JP - Giappone 19
HK - Hong Kong 18
PL - Polonia 11
FI - Finlandia 9
IR - Iran 8
FR - Francia 7
GR - Grecia 7
NL - Olanda 7
BE - Belgio 6
CR - Costa Rica 6
UA - Ucraina 6
AU - Australia 5
BR - Brasile 5
KR - Corea 5
MA - Marocco 5
PH - Filippine 4
PK - Pakistan 4
CH - Svizzera 3
EC - Ecuador 3
EG - Egitto 3
ID - Indonesia 3
MX - Messico 3
NG - Nigeria 3
BH - Bahrain 2
CL - Cile 2
IE - Irlanda 2
IL - Israele 2
PE - Perù 2
RS - Serbia 2
SV - El Salvador 2
UY - Uruguay 2
VE - Venezuela 2
ZA - Sudafrica 2
A1 - Anonimo 1
AR - Argentina 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
MT - Malta 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.676
Salva come PNG Salva come JPEG
Città #
Chandler 323
Milan 284
Fairfield 258
Ashburn 188
Woodbridge 169
Houston 142
Seattle 134
Sofia 129
Wilmington 121
Cambridge 96
New York 90
Abidjan 75
Princeton 72
Ann Arbor 66
Vienna 55
Beijing 51
Lawrence 51
London 51
Dakar 40
Florence 39
Medford 38
Rome 38
Frankfurt am Main 36
Redwood City 30
Serra 30
Boulder 29
Dong Ket 25
Pisa 23
Dearborn 22
Redmond 22
Bremen 21
San Diego 21
Ottawa 20
Washington 19
Des Moines 17
Hong Kong 16
Scandicci 12
Chiesina Uzzanese 10
Tokyo 10
Izmir 9
Hefei 8
Lancaster 8
Nanchang 8
Nanjing 8
Tianjin 7
Amsterdam 6
Kocaeli 6
Montreal 6
Salt Lake City 6
San José 6
Shanghai 6
Shenyang 6
Brussels 5
Istanbul 5
Jiaxing 5
Ningbo 5
Norwalk 5
Phoenix 5
Samsun 5
Singapore 5
Urmia 5
Zhengzhou 5
Duncan 4
Edinburgh 4
Jinan 4
Napoli 4
Toronto 4
Atakum 3
Bangalore 3
Cleveland 3
Hatfield 3
Hebei 3
Jakarta 3
Kunming 3
Lagos 3
Los Angeles 3
Mumbai 3
Munich 3
Stuttgart 3
Vicopisano 3
Angri 2
Bari 2
Baton Rouge 2
Belgrade 2
Bientina 2
Bologna 2
Calcinaia 2
Campiglia Marittima 2
Cellole 2
Changsha 2
Crick 2
Dublin 2
Epsom 2
Geneva 2
Genoa 2
Gurgaon 2
Haikou 2
Hyderabad 2
Islamabad 2
Johannesburg 2
Totale 3.112
Salva come PNG Salva come JPEG
Nome #
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 173
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 159
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 150
Targeted Therapy in Thyroid Cancer: State of the Art 149
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 145
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 141
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 141
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 140
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 131
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 130
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 128
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 125
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 121
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 120
Il carcinoma tiroideo: nuove prospettive terapeutiche. 119
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 116
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 113
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 109
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 108
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 108
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 104
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 102
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 99
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 97
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 97
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 91
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 89
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 89
null 84
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 84
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 81
Role of oxidative stress in radio-induced DNA damage and in RET/PTC rearrangement in papillary thyroid cancer 80
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 77
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 71
Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study 66
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 65
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 64
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 60
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 58
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 57
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 56
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 52
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 49
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 48
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer 47
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 43
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 42
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 37
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 37
FDG-PET/CT Correlates with the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival 37
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 35
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 33
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 30
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 15
Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination 7
Totale 4.809
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.756
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.756
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019171 0 0 0 0 0 0 0 0 0 40 76 55
2019/20201.109 65 69 85 91 111 127 124 77 98 92 149 21
2020/2021471 59 20 59 14 18 76 19 28 35 40 31 72
2021/2022607 16 14 14 25 132 83 14 27 39 37 46 160
2022/20231.221 162 187 90 89 110 124 27 98 232 14 79 9
2023/2024788 91 118 133 85 144 154 29 20 10 4 0 0
Totale 4.809